| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 176 | 2024 | 5061 | 7.900 |
Why?
|
| Adenocarcinoma | 106 | 2023 | 7789 | 3.920 |
Why?
|
| Carcinoma, Pancreatic Ductal | 50 | 2024 | 1724 | 3.440 |
Why?
|
| Deoxycytidine | 58 | 2022 | 1353 | 2.870 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 94 | 2023 | 15862 | 2.640 |
Why?
|
| Pancreaticoduodenectomy | 44 | 2023 | 690 | 2.250 |
Why?
|
| Colorectal Neoplasms | 37 | 2024 | 3578 | 2.020 |
Why?
|
| Neoadjuvant Therapy | 55 | 2023 | 4975 | 1.860 |
Why?
|
| Pancreatectomy | 26 | 2022 | 652 | 1.780 |
Why?
|
| Intestinal Neoplasms | 9 | 2021 | 189 | 1.740 |
Why?
|
| Ampulla of Vater | 13 | 2023 | 155 | 1.630 |
Why?
|
| Fluorouracil | 52 | 2021 | 1944 | 1.490 |
Why?
|
| Common Bile Duct Neoplasms | 11 | 2023 | 145 | 1.440 |
Why?
|
| Intestine, Small | 10 | 2021 | 499 | 1.440 |
Why?
|
| Liver Neoplasms | 29 | 2024 | 4557 | 1.280 |
Why?
|
| Chemotherapy, Adjuvant | 40 | 2020 | 3890 | 1.260 |
Why?
|
| Bevacizumab | 18 | 2022 | 938 | 1.230 |
Why?
|
| Preoperative Care | 14 | 2021 | 1529 | 1.190 |
Why?
|
| Aged | 210 | 2023 | 70117 | 1.170 |
Why?
|
| Middle Aged | 219 | 2024 | 86204 | 1.100 |
Why?
|
| Antineoplastic Agents | 49 | 2022 | 14289 | 1.100 |
Why?
|
| Anus Neoplasms | 8 | 2020 | 411 | 1.090 |
Why?
|
| Combined Modality Therapy | 57 | 2020 | 8865 | 1.070 |
Why?
|
| Albumins | 9 | 2022 | 258 | 1.030 |
Why?
|
| Antimetabolites, Antineoplastic | 29 | 2020 | 1299 | 1.000 |
Why?
|
| Humans | 339 | 2024 | 261506 | 0.980 |
Why?
|
| Male | 238 | 2024 | 123000 | 0.970 |
Why?
|
| Neoplasm Staging | 67 | 2023 | 13658 | 0.970 |
Why?
|
| Radiotherapy, Adjuvant | 27 | 2013 | 2231 | 0.960 |
Why?
|
| Adult | 182 | 2023 | 77950 | 0.950 |
Why?
|
| Organoplatinum Compounds | 17 | 2020 | 702 | 0.900 |
Why?
|
| Duodenal Neoplasms | 6 | 2023 | 138 | 0.890 |
Why?
|
| Female | 240 | 2024 | 141928 | 0.890 |
Why?
|
| Carcinoma, Hepatocellular | 14 | 2024 | 2027 | 0.880 |
Why?
|
| Disease-Free Survival | 48 | 2022 | 10001 | 0.840 |
Why?
|
| Aged, 80 and over | 107 | 2022 | 29902 | 0.830 |
Why?
|
| Paclitaxel | 13 | 2022 | 1996 | 0.820 |
Why?
|
| Biomarkers, Tumor | 29 | 2021 | 10331 | 0.800 |
Why?
|
| Chemoradiotherapy, Adjuvant | 9 | 2017 | 565 | 0.790 |
Why?
|
| Neoplasm Recurrence, Local | 34 | 2023 | 10035 | 0.790 |
Why?
|
| Prognosis | 66 | 2023 | 21713 | 0.770 |
Why?
|
| Appendiceal Neoplasms | 7 | 2023 | 234 | 0.750 |
Why?
|
| Chemoradiotherapy | 13 | 2019 | 1946 | 0.750 |
Why?
|
| Colonic Neoplasms | 8 | 2023 | 1390 | 0.730 |
Why?
|
| Capecitabine | 22 | 2022 | 388 | 0.730 |
Why?
|
| Retrospective Studies | 98 | 2023 | 37905 | 0.720 |
Why?
|
| Radiosurgery | 8 | 2023 | 1330 | 0.720 |
Why?
|
| Rectal Neoplasms | 15 | 2022 | 1202 | 0.690 |
Why?
|
| Treatment Outcome | 83 | 2022 | 32848 | 0.690 |
Why?
|
| Neoplasm Metastasis | 32 | 2020 | 5112 | 0.660 |
Why?
|
| Hematology | 2 | 2019 | 104 | 0.640 |
Why?
|
| Kaplan-Meier Estimate | 35 | 2020 | 6207 | 0.630 |
Why?
|
| Survival Rate | 46 | 2020 | 12221 | 0.580 |
Why?
|
| Angiogenesis Inhibitors | 8 | 2016 | 1248 | 0.570 |
Why?
|
| Medical Oncology | 4 | 2020 | 1423 | 0.560 |
Why?
|
| Fellowships and Scholarships | 2 | 2019 | 390 | 0.530 |
Why?
|
| Camptothecin | 10 | 2020 | 517 | 0.520 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 8 | 2021 | 1331 | 0.520 |
Why?
|
| Antibodies, Monoclonal | 18 | 2022 | 4367 | 0.500 |
Why?
|
| Embolization, Therapeutic | 6 | 2020 | 551 | 0.490 |
Why?
|
| Patient Care | 2 | 2020 | 149 | 0.470 |
Why?
|
| Carcinoma, Squamous Cell | 8 | 2020 | 5437 | 0.470 |
Why?
|
| Follow-Up Studies | 40 | 2021 | 14889 | 0.460 |
Why?
|
| Brain Neoplasms | 7 | 2022 | 4849 | 0.450 |
Why?
|
| Bile Duct Neoplasms | 5 | 2022 | 493 | 0.440 |
Why?
|
| Survival Analysis | 36 | 2020 | 9180 | 0.440 |
Why?
|
| Social Networking | 1 | 2012 | 28 | 0.430 |
Why?
|
| Cetuximab | 7 | 2017 | 472 | 0.420 |
Why?
|
| ErbB Receptors | 9 | 2020 | 2295 | 0.410 |
Why?
|
| Antibodies, Monoclonal, Humanized | 19 | 2022 | 3251 | 0.390 |
Why?
|
| Mutation | 16 | 2021 | 15179 | 0.380 |
Why?
|
| CA-19-9 Antigen | 7 | 2022 | 144 | 0.380 |
Why?
|
| Gallbladder Neoplasms | 5 | 2015 | 245 | 0.380 |
Why?
|
| Cholangiocarcinoma | 6 | 2022 | 493 | 0.380 |
Why?
|
| Neoplasms | 15 | 2022 | 15193 | 0.370 |
Why?
|
| Hepatic Artery | 3 | 2020 | 240 | 0.370 |
Why?
|
| Leucovorin | 10 | 2020 | 332 | 0.370 |
Why?
|
| Smad4 Protein | 1 | 2011 | 196 | 0.360 |
Why?
|
| Carcinoma, Signet Ring Cell | 3 | 2019 | 170 | 0.360 |
Why?
|
| Metastasectomy | 3 | 2021 | 200 | 0.350 |
Why?
|
| Patient Selection | 11 | 2020 | 2055 | 0.350 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2015 | 833 | 0.350 |
Why?
|
| Drug Administration Schedule | 16 | 2020 | 3472 | 0.340 |
Why?
|
| Peritoneal Neoplasms | 5 | 2019 | 821 | 0.340 |
Why?
|
| Randomized Controlled Trials as Topic | 10 | 2022 | 2594 | 0.340 |
Why?
|
| Insulin-Like Growth Factor I | 4 | 2020 | 630 | 0.330 |
Why?
|
| Induction Chemotherapy | 6 | 2023 | 669 | 0.330 |
Why?
|
| Trifluridine | 3 | 2018 | 30 | 0.320 |
Why?
|
| Quality-Adjusted Life Years | 5 | 2023 | 226 | 0.310 |
Why?
|
| Liver | 6 | 2020 | 2961 | 0.310 |
Why?
|
| Cisplatin | 11 | 2019 | 2432 | 0.300 |
Why?
|
| Cost-Benefit Analysis | 7 | 2023 | 945 | 0.300 |
Why?
|
| Technology Assessment, Biomedical | 4 | 2023 | 59 | 0.300 |
Why?
|
| Erlotinib Hydrochloride | 7 | 2019 | 388 | 0.300 |
Why?
|
| Biliary Tract Neoplasms | 2 | 2022 | 167 | 0.300 |
Why?
|
| Tomography, X-Ray Computed | 16 | 2021 | 7551 | 0.290 |
Why?
|
| Exosomes | 3 | 2018 | 253 | 0.290 |
Why?
|
| Receptors, Somatomedin | 2 | 2018 | 70 | 0.290 |
Why?
|
| Pancreas | 7 | 2023 | 718 | 0.290 |
Why?
|
| Intracranial Arteriovenous Malformations | 2 | 2018 | 41 | 0.280 |
Why?
|
| Chemoembolization, Therapeutic | 3 | 2024 | 181 | 0.280 |
Why?
|
| Positron-Emission Tomography | 1 | 2015 | 2173 | 0.280 |
Why?
|
| Lymphatic Metastasis | 17 | 2020 | 4844 | 0.280 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2022 | 665 | 0.280 |
Why?
|
| Circulating Tumor DNA | 2 | 2019 | 235 | 0.270 |
Why?
|
| Proportional Hazards Models | 14 | 2021 | 4988 | 0.270 |
Why?
|
| Adenocarcinoma, Mucinous | 3 | 2017 | 436 | 0.270 |
Why?
|
| Hypersplenism | 2 | 2020 | 23 | 0.270 |
Why?
|
| Molecular Targeted Therapy | 5 | 2019 | 2330 | 0.270 |
Why?
|
| Ceramides | 3 | 1995 | 95 | 0.260 |
Why?
|
| Phthalazines | 2 | 2021 | 253 | 0.260 |
Why?
|
| Risk Factors | 28 | 2021 | 17523 | 0.240 |
Why?
|
| Multivariate Analysis | 16 | 2021 | 4298 | 0.240 |
Why?
|
| PTEN Phosphohydrolase | 4 | 2013 | 986 | 0.240 |
Why?
|
| Carcinoma | 3 | 2017 | 2578 | 0.240 |
Why?
|
| Time Factors | 22 | 2021 | 12926 | 0.240 |
Why?
|
| Radiation-Sensitizing Agents | 7 | 2017 | 363 | 0.240 |
Why?
|
| Phosphatidylinositol 3-Kinases | 4 | 2014 | 1678 | 0.230 |
Why?
|
| Patient Care Team | 2 | 2009 | 795 | 0.230 |
Why?
|
| Anal Canal | 7 | 2017 | 238 | 0.230 |
Why?
|
| Prospective Studies | 20 | 2022 | 12873 | 0.230 |
Why?
|
| Mesenteric Artery, Superior | 2 | 2015 | 71 | 0.230 |
Why?
|
| Protein Kinase Inhibitors | 9 | 2019 | 4757 | 0.230 |
Why?
|
| Uracil | 4 | 2018 | 64 | 0.220 |
Why?
|
| Suction | 4 | 2004 | 104 | 0.220 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2003 | 66 | 0.220 |
Why?
|
| Esophageal Neoplasms | 2 | 2015 | 3168 | 0.220 |
Why?
|
| Jejunal Neoplasms | 3 | 2011 | 34 | 0.220 |
Why?
|
| Ileal Neoplasms | 3 | 2011 | 47 | 0.220 |
Why?
|
| Lung Neoplasms | 8 | 2024 | 11538 | 0.220 |
Why?
|
| Neoplasm Grading | 9 | 2018 | 1742 | 0.220 |
Why?
|
| DNA Mutational Analysis | 6 | 2019 | 2283 | 0.220 |
Why?
|
| Pandemics | 3 | 2020 | 1559 | 0.220 |
Why?
|
| TOR Serine-Threonine Kinases | 4 | 2014 | 1546 | 0.210 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2023 | 108 | 0.210 |
Why?
|
| Lymph Nodes | 4 | 2015 | 2967 | 0.210 |
Why?
|
| Palliative Care | 6 | 2019 | 2037 | 0.210 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 651 | 0.210 |
Why?
|
| Radiotherapy Dosage | 18 | 2016 | 3842 | 0.210 |
Why?
|
| Antineoplastic Protocols | 1 | 2022 | 33 | 0.210 |
Why?
|
| Retreatment | 3 | 2018 | 452 | 0.210 |
Why?
|
| Maximum Tolerated Dose | 9 | 2018 | 1290 | 0.210 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 715 | 0.210 |
Why?
|
| Young Adult | 22 | 2021 | 21445 | 0.200 |
Why?
|
| Quinazolines | 5 | 2015 | 923 | 0.200 |
Why?
|
| Salvage Therapy | 4 | 2022 | 2054 | 0.200 |
Why?
|
| Chemoprevention | 1 | 2003 | 241 | 0.200 |
Why?
|
| Proto-Oncogene Proteins B-raf | 4 | 2017 | 1283 | 0.200 |
Why?
|
| Neoplasm Proteins | 5 | 2018 | 3230 | 0.200 |
Why?
|
| Clinical Trials as Topic | 8 | 2017 | 3719 | 0.200 |
Why?
|
| Cohort Studies | 16 | 2020 | 9244 | 0.200 |
Why?
|
| Multidetector Computed Tomography | 2 | 2013 | 150 | 0.200 |
Why?
|
| Disease Management | 4 | 2019 | 1052 | 0.190 |
Why?
|
| Electrocoagulation | 1 | 2021 | 65 | 0.190 |
Why?
|
| Radiotherapy | 8 | 2009 | 1824 | 0.190 |
Why?
|
| Splenic Infarction | 1 | 2020 | 14 | 0.190 |
Why?
|
| Fibrinolytic Agents | 1 | 2003 | 324 | 0.190 |
Why?
|
| Risk Assessment | 11 | 2017 | 6869 | 0.190 |
Why?
|
| Severity of Illness Index | 4 | 2021 | 4320 | 0.190 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2022 | 1249 | 0.190 |
Why?
|
| CD40 Antigens | 1 | 2021 | 104 | 0.180 |
Why?
|
| Sezary Syndrome | 1 | 2021 | 159 | 0.180 |
Why?
|
| Spleen | 3 | 2020 | 676 | 0.180 |
Why?
|
| Bile Ducts, Intrahepatic | 4 | 2022 | 334 | 0.180 |
Why?
|
| Basal Ganglia Hemorrhage | 3 | 2004 | 4 | 0.180 |
Why?
|
| Febrile Neutropenia | 1 | 2020 | 65 | 0.180 |
Why?
|
| Arteriovenous Fistula | 2 | 2018 | 92 | 0.180 |
Why?
|
| Jaundice, Obstructive | 2 | 2010 | 16 | 0.180 |
Why?
|
| Microwaves | 2 | 2024 | 32 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-akt | 5 | 2014 | 2054 | 0.180 |
Why?
|
| Acinar Cells | 1 | 2019 | 53 | 0.170 |
Why?
|
| Texas | 10 | 2020 | 6311 | 0.170 |
Why?
|
| Predictive Value of Tests | 10 | 2021 | 4892 | 0.170 |
Why?
|
| Aspirin | 1 | 2022 | 455 | 0.170 |
Why?
|
| Microsatellite Instability | 5 | 2023 | 400 | 0.170 |
Why?
|
| Polymorphism, Genetic | 6 | 2006 | 1450 | 0.170 |
Why?
|
| Models, Theoretical | 2 | 2020 | 785 | 0.170 |
Why?
|
| Carcinoma, Neuroendocrine | 2 | 2017 | 716 | 0.170 |
Why?
|
| Carboplatin | 3 | 2018 | 823 | 0.170 |
Why?
|
| Stereotaxic Techniques | 3 | 2004 | 172 | 0.170 |
Why?
|
| Case-Control Studies | 13 | 2021 | 6100 | 0.160 |
Why?
|
| Tumor Burden | 7 | 2020 | 1987 | 0.160 |
Why?
|
| Postoperative Care | 2 | 2020 | 739 | 0.160 |
Why?
|
| Markov Chains | 2 | 2016 | 175 | 0.160 |
Why?
|
| Disease Progression | 12 | 2018 | 6682 | 0.160 |
Why?
|
| Mycosis Fungoides | 1 | 2021 | 320 | 0.160 |
Why?
|
| Neoplasm Invasiveness | 9 | 2017 | 3981 | 0.160 |
Why?
|
| Betacoronavirus | 2 | 2020 | 527 | 0.160 |
Why?
|
| Skin Neoplasms | 3 | 2021 | 4654 | 0.160 |
Why?
|
| Fibroblast Growth Factors | 1 | 2019 | 257 | 0.150 |
Why?
|
| Diet, High-Fat | 1 | 2019 | 241 | 0.150 |
Why?
|
| Sirolimus | 3 | 2012 | 814 | 0.150 |
Why?
|
| Quality of Life | 4 | 2024 | 4532 | 0.150 |
Why?
|
| Intracranial Hemorrhages | 1 | 2018 | 121 | 0.150 |
Why?
|
| F-Box-WD Repeat-Containing Protein 7 | 1 | 2017 | 83 | 0.150 |
Why?
|
| Bacterial Infections | 1 | 2021 | 479 | 0.150 |
Why?
|
| Gastrointestinal Neoplasms | 4 | 2020 | 600 | 0.150 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 2 | 2008 | 168 | 0.150 |
Why?
|
| Pancreatic Ducts | 1 | 2018 | 122 | 0.150 |
Why?
|
| Ipilimumab | 1 | 2022 | 710 | 0.150 |
Why?
|
| Radiotherapy, Intensity-Modulated | 3 | 2017 | 2104 | 0.150 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2024 | 992 | 0.150 |
Why?
|
| Genetic Testing | 2 | 2019 | 1589 | 0.150 |
Why?
|
| src-Family Kinases | 2 | 2017 | 478 | 0.150 |
Why?
|
| Organs at Risk | 2 | 2017 | 514 | 0.150 |
Why?
|
| Argininosuccinate Synthase | 1 | 2017 | 54 | 0.150 |
Why?
|
| Codon | 1 | 2017 | 241 | 0.150 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2017 | 105 | 0.140 |
Why?
|
| Sensitivity and Specificity | 6 | 2022 | 4971 | 0.140 |
Why?
|
| Glypicans | 1 | 2016 | 51 | 0.140 |
Why?
|
| Cytotoxins | 1 | 2016 | 66 | 0.140 |
Why?
|
| Thrombosis | 1 | 2003 | 781 | 0.140 |
Why?
|
| Immunohistochemistry | 11 | 2018 | 7548 | 0.140 |
Why?
|
| Antigens, Neoplasm | 2 | 2020 | 1506 | 0.140 |
Why?
|
| Biopsy, Fine-Needle | 3 | 2009 | 690 | 0.140 |
Why?
|
| Research Report | 1 | 2017 | 144 | 0.140 |
Why?
|
| Tumor Microenvironment | 6 | 2023 | 2864 | 0.140 |
Why?
|
| Germ-Line Mutation | 2 | 2019 | 1046 | 0.140 |
Why?
|
| Chi-Square Distribution | 8 | 2015 | 1323 | 0.140 |
Why?
|
| Quality of Health Care | 2 | 2018 | 621 | 0.140 |
Why?
|
| Obesity | 3 | 2022 | 2884 | 0.140 |
Why?
|
| Carcinoma, Islet Cell | 3 | 2008 | 35 | 0.140 |
Why?
|
| Pancreatic Fistula | 1 | 2016 | 99 | 0.140 |
Why?
|
| Placebos | 3 | 2011 | 437 | 0.140 |
Why?
|
| Cytoreduction Surgical Procedures | 2 | 2017 | 475 | 0.140 |
Why?
|
| Phosphoprotein Phosphatases | 2 | 1994 | 214 | 0.140 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2024 | 5319 | 0.130 |
Why?
|
| Cholestasis | 2 | 2008 | 203 | 0.130 |
Why?
|
| DNA-Binding Proteins | 5 | 2020 | 4821 | 0.130 |
Why?
|
| Benzodioxoles | 1 | 2015 | 29 | 0.130 |
Why?
|
| Parenteral Nutrition, Total | 1 | 2015 | 140 | 0.130 |
Why?
|
| Cachexia | 1 | 2017 | 161 | 0.130 |
Why?
|
| Robotic Surgical Procedures | 2 | 2020 | 481 | 0.130 |
Why?
|
| Age Factors | 8 | 2020 | 5377 | 0.130 |
Why?
|
| Brain | 6 | 2018 | 4113 | 0.130 |
Why?
|
| Biopsy | 3 | 2018 | 3443 | 0.130 |
Why?
|
| Radiotherapy, Conformal | 2 | 2017 | 902 | 0.130 |
Why?
|
| Polyurethanes | 1 | 2014 | 36 | 0.130 |
Why?
|
| Body Mass Index | 3 | 2022 | 2203 | 0.130 |
Why?
|
| Pseudomyxoma Peritonei | 1 | 2015 | 38 | 0.130 |
Why?
|
| Intestinal Obstruction | 2 | 2015 | 202 | 0.120 |
Why?
|
| Migraine Disorders | 1 | 2015 | 79 | 0.120 |
Why?
|
| Lymphopenia | 1 | 2016 | 199 | 0.120 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2015 | 82 | 0.120 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2019 | 2359 | 0.120 |
Why?
|
| DNA Repair | 3 | 2007 | 1872 | 0.120 |
Why?
|
| Stents | 3 | 2008 | 1096 | 0.120 |
Why?
|
| Educational Status | 1 | 2015 | 397 | 0.120 |
Why?
|
| Double-Blind Method | 3 | 2023 | 2588 | 0.120 |
Why?
|
| Thrombocytosis | 1 | 2015 | 121 | 0.120 |
Why?
|
| Curriculum | 2 | 2019 | 860 | 0.120 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2019 | 973 | 0.120 |
Why?
|
| Reproducibility of Results | 4 | 2020 | 6009 | 0.120 |
Why?
|
| Portal Vein | 2 | 2007 | 355 | 0.120 |
Why?
|
| DNA, Satellite | 2 | 1991 | 36 | 0.120 |
Why?
|
| Radiation Injuries | 2 | 2018 | 1411 | 0.120 |
Why?
|
| Incidence | 10 | 2017 | 5673 | 0.120 |
Why?
|
| Sex Characteristics | 2 | 2015 | 417 | 0.120 |
Why?
|
| Subacute Care | 2 | 2003 | 11 | 0.110 |
Why?
|
| Intracranial Aneurysm | 1 | 2014 | 123 | 0.110 |
Why?
|
| Indoles | 2 | 2011 | 1009 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 10 | 2008 | 4938 | 0.110 |
Why?
|
| Dasatinib | 1 | 2017 | 862 | 0.110 |
Why?
|
| Cerebral Hemorrhage | 1 | 2014 | 183 | 0.110 |
Why?
|
| Down-Regulation | 2 | 2019 | 2074 | 0.110 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2019 | 8873 | 0.110 |
Why?
|
| Education, Medical, Graduate | 1 | 2019 | 671 | 0.110 |
Why?
|
| Second Messenger Systems | 1 | 1993 | 39 | 0.110 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2017 | 5178 | 0.110 |
Why?
|
| Analysis of Variance | 4 | 2013 | 2307 | 0.110 |
Why?
|
| Program Evaluation | 1 | 2015 | 597 | 0.110 |
Why?
|
| Neurocytoma | 1 | 2012 | 17 | 0.110 |
Why?
|
| DNA Methylation | 3 | 2019 | 2669 | 0.110 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2021 | 907 | 0.110 |
Why?
|
| Receptor, ErbB-2 | 3 | 2015 | 2518 | 0.110 |
Why?
|
| Third Ventricle | 1 | 2012 | 37 | 0.110 |
Why?
|
| Postoperative Complications | 6 | 2016 | 5542 | 0.110 |
Why?
|
| Endosonography | 2 | 2008 | 536 | 0.110 |
Why?
|
| Hydroxamic Acids | 1 | 2015 | 442 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 2 | 2022 | 2992 | 0.100 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2020 | 3552 | 0.100 |
Why?
|
| Ovarian Neoplasms | 2 | 2024 | 4638 | 0.100 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 2 | 2011 | 355 | 0.100 |
Why?
|
| Mutation, Missense | 1 | 2017 | 1152 | 0.100 |
Why?
|
| Smoking | 5 | 2007 | 2440 | 0.100 |
Why?
|
| High-Throughput Nucleotide Sequencing | 5 | 2020 | 2291 | 0.100 |
Why?
|
| Actuarial Analysis | 1 | 2011 | 159 | 0.100 |
Why?
|
| Cerebral Ventricle Neoplasms | 1 | 2012 | 81 | 0.100 |
Why?
|
| Decision Support Techniques | 2 | 2016 | 622 | 0.100 |
Why?
|
| Bilirubin | 2 | 2013 | 221 | 0.100 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2013 | 167 | 0.100 |
Why?
|
| Pyrimidines | 2 | 2015 | 3518 | 0.100 |
Why?
|
| Feasibility Studies | 4 | 2019 | 2292 | 0.100 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2019 | 1209 | 0.100 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2017 | 799 | 0.100 |
Why?
|
| Image Processing, Computer-Assisted | 5 | 2022 | 1648 | 0.100 |
Why?
|
| Cytokines | 3 | 2017 | 2809 | 0.100 |
Why?
|
| Adolescent | 15 | 2020 | 31252 | 0.100 |
Why?
|
| Self-Help Groups | 1 | 2011 | 37 | 0.100 |
Why?
|
| Clinical Decision-Making | 3 | 2020 | 524 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2019 | 5539 | 0.100 |
Why?
|
| Stroke Volume | 1 | 2014 | 577 | 0.100 |
Why?
|
| Neoplasm, Residual | 3 | 2015 | 1656 | 0.100 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1991 | 239 | 0.100 |
Why?
|
| Maintenance Chemotherapy | 1 | 2011 | 202 | 0.100 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2015 | 612 | 0.100 |
Why?
|
| Antibiotics, Antineoplastic | 3 | 2012 | 726 | 0.100 |
Why?
|
| Guidelines as Topic | 2 | 2014 | 383 | 0.090 |
Why?
|
| Bias | 2 | 2022 | 205 | 0.090 |
Why?
|
| Cross-Sectional Studies | 2 | 2022 | 4314 | 0.090 |
Why?
|
| Platelet Count | 3 | 2020 | 490 | 0.090 |
Why?
|
| Calibration | 2 | 2022 | 337 | 0.090 |
Why?
|
| Drug Delivery Systems | 1 | 2014 | 669 | 0.090 |
Why?
|
| Breast Neoplasms | 5 | 2020 | 15694 | 0.090 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2012 | 330 | 0.090 |
Why?
|
| Health Status | 1 | 2013 | 590 | 0.090 |
Why?
|
| Sulfonamides | 3 | 2015 | 1823 | 0.090 |
Why?
|
| Antineoplastic Agents, Phytogenic | 4 | 2020 | 852 | 0.090 |
Why?
|
| Odds Ratio | 5 | 2016 | 2316 | 0.090 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 1945 | 0.090 |
Why?
|
| Mitomycin | 2 | 2009 | 208 | 0.090 |
Why?
|
| Transcription Factors | 3 | 2020 | 5270 | 0.090 |
Why?
|
| Carcinoma in Situ | 1 | 2013 | 487 | 0.090 |
Why?
|
| Disclosure | 1 | 2011 | 181 | 0.090 |
Why?
|
| Myocardial Infarction | 6 | 1997 | 1374 | 0.090 |
Why?
|
| United States | 8 | 2021 | 15433 | 0.090 |
Why?
|
| Splenomegaly | 1 | 2010 | 158 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 1994 | 810 | 0.090 |
Why?
|
| Signal Transduction | 7 | 2019 | 11965 | 0.090 |
Why?
|
| Immunotherapy | 2 | 2023 | 3341 | 0.090 |
Why?
|
| Isoflavones | 1 | 2010 | 72 | 0.090 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 3 | 2020 | 521 | 0.090 |
Why?
|
| Drug Combinations | 4 | 2018 | 621 | 0.090 |
Why?
|
| Inflammation | 2 | 2017 | 2522 | 0.090 |
Why?
|
| Prevalence | 2 | 2015 | 3260 | 0.090 |
Why?
|
| Neutropenia | 3 | 2009 | 968 | 0.090 |
Why?
|
| Population Surveillance | 1 | 2013 | 627 | 0.090 |
Why?
|
| Oxaloacetates | 1 | 2008 | 7 | 0.080 |
Why?
|
| Child Development Disorders, Pervasive | 1 | 2010 | 96 | 0.080 |
Why?
|
| DNA | 1 | 2017 | 2693 | 0.080 |
Why?
|
| Hepatic Veno-Occlusive Disease | 1 | 2010 | 122 | 0.080 |
Why?
|
| BRCA2 Protein | 1 | 2011 | 358 | 0.080 |
Why?
|
| Laparoscopy | 1 | 2018 | 1225 | 0.080 |
Why?
|
| Platinum Compounds | 1 | 2008 | 131 | 0.080 |
Why?
|
| Hypertension, Portal | 1 | 2009 | 124 | 0.080 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2007 | 4549 | 0.080 |
Why?
|
| Genomics | 1 | 2019 | 2738 | 0.080 |
Why?
|
| Treatment Failure | 4 | 2017 | 1391 | 0.080 |
Why?
|
| Surveys and Questionnaires | 3 | 2019 | 5687 | 0.080 |
Why?
|
| Thymine | 3 | 2018 | 46 | 0.080 |
Why?
|
| Digestive System Surgical Procedures | 2 | 2017 | 275 | 0.080 |
Why?
|
| Bayes Theorem | 2 | 2023 | 1021 | 0.080 |
Why?
|
| Preoperative Period | 2 | 2020 | 344 | 0.080 |
Why?
|
| Octreotide | 1 | 2008 | 118 | 0.080 |
Why?
|
| Biliary Tract Diseases | 1 | 2008 | 61 | 0.080 |
Why?
|
| Pyrrolidines | 3 | 2018 | 113 | 0.080 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2020 | 2390 | 0.080 |
Why?
|
| Tissue Array Analysis | 3 | 2015 | 760 | 0.080 |
Why?
|
| Radiography | 3 | 2020 | 1904 | 0.080 |
Why?
|
| Neovascularization, Pathologic | 1 | 2015 | 1547 | 0.080 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 1 | 2007 | 123 | 0.080 |
Why?
|
| Gastric Outlet Obstruction | 1 | 2007 | 31 | 0.080 |
Why?
|
| Hyperthermia, Induced | 2 | 2010 | 510 | 0.080 |
Why?
|
| Curcumin | 1 | 2008 | 117 | 0.080 |
Why?
|
| Liquid Biopsy | 2 | 2018 | 158 | 0.080 |
Why?
|
| Tobacco, Smokeless | 1 | 2007 | 28 | 0.080 |
Why?
|
| BRCA1 Protein | 2 | 2021 | 493 | 0.080 |
Why?
|
| Administration, Oral | 5 | 2015 | 1544 | 0.080 |
Why?
|
| Diagnostic Imaging | 3 | 2012 | 1162 | 0.070 |
Why?
|
| Interferon-alpha | 1 | 2011 | 889 | 0.070 |
Why?
|
| Intestinal Perforation | 1 | 2007 | 102 | 0.070 |
Why?
|
| Infusions, Intra-Arterial | 2 | 2020 | 171 | 0.070 |
Why?
|
| DNA Glycosylases | 1 | 2007 | 93 | 0.070 |
Why?
|
| Gene Expression Profiling | 3 | 2020 | 5159 | 0.070 |
Why?
|
| Thrombocytopenia | 2 | 2011 | 846 | 0.070 |
Why?
|
| Radiation Dosage | 3 | 2020 | 1014 | 0.070 |
Why?
|
| Tubulin Modulators | 1 | 2006 | 65 | 0.070 |
Why?
|
| Epothilones | 1 | 2006 | 54 | 0.070 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2011 | 479 | 0.070 |
Why?
|
| Research Design | 2 | 2011 | 1544 | 0.070 |
Why?
|
| Multiple Myeloma | 1 | 2018 | 2138 | 0.070 |
Why?
|
| Recurrence | 5 | 2018 | 4758 | 0.070 |
Why?
|
| Aging | 1 | 2015 | 1582 | 0.070 |
Why?
|
| Interdisciplinary Communication | 1 | 2008 | 280 | 0.070 |
Why?
|
| Peptic Ulcer Hemorrhage | 1 | 2006 | 34 | 0.070 |
Why?
|
| Oncogenes | 1 | 2009 | 673 | 0.070 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2007 | 105 | 0.070 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2006 | 153 | 0.070 |
Why?
|
| Etoposide | 2 | 2018 | 870 | 0.070 |
Why?
|
| Genetic Linkage | 4 | 1998 | 512 | 0.070 |
Why?
|
| Digestive System | 1 | 2006 | 114 | 0.070 |
Why?
|
| Hepatitis B | 1 | 2008 | 258 | 0.070 |
Why?
|
| DNA Mismatch Repair | 2 | 2022 | 268 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2022 | 7702 | 0.070 |
Why?
|
| Confidence Intervals | 2 | 2020 | 756 | 0.070 |
Why?
|
| Benzamides | 1 | 2011 | 1832 | 0.070 |
Why?
|
| Arylamine N-Acetyltransferase | 1 | 2005 | 41 | 0.070 |
Why?
|
| Imaging, Three-Dimensional | 3 | 2022 | 925 | 0.070 |
Why?
|
| Algorithms | 4 | 2018 | 3890 | 0.070 |
Why?
|
| Survivors | 1 | 2011 | 1031 | 0.060 |
Why?
|
| Drainage | 1 | 2007 | 416 | 0.060 |
Why?
|
| Taxoids | 2 | 2023 | 967 | 0.060 |
Why?
|
| Immunophenotyping | 1 | 2009 | 1681 | 0.060 |
Why?
|
| Cytochrome P-450 CYP1A2 | 1 | 2005 | 63 | 0.060 |
Why?
|
| Cell Line, Tumor | 5 | 2020 | 14551 | 0.060 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2005 | 102 | 0.060 |
Why?
|
| Statistics, Nonparametric | 4 | 2013 | 980 | 0.060 |
Why?
|
| Remission Induction | 1 | 2011 | 3569 | 0.060 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2018 | 347 | 0.060 |
Why?
|
| Melanoma | 2 | 2019 | 5317 | 0.060 |
Why?
|
| Cadherins | 2 | 2019 | 660 | 0.060 |
Why?
|
| Immunologic Factors | 2 | 2022 | 649 | 0.060 |
Why?
|
| CpG Islands | 2 | 2018 | 633 | 0.060 |
Why?
|
| Animals | 15 | 2023 | 59536 | 0.060 |
Why?
|
| Forecasting | 1 | 2007 | 694 | 0.060 |
Why?
|
| Mesenteric Veins | 1 | 2004 | 73 | 0.060 |
Why?
|
| Pyridines | 1 | 2011 | 1244 | 0.060 |
Why?
|
| Radiotherapy, High-Energy | 1 | 2005 | 295 | 0.060 |
Why?
|
| Everolimus | 3 | 2012 | 415 | 0.060 |
Why?
|
| Nausea | 2 | 2007 | 525 | 0.060 |
Why?
|
| Neurosurgical Procedures | 2 | 2014 | 609 | 0.060 |
Why?
|
| DNA Adducts | 2 | 2014 | 210 | 0.060 |
Why?
|
| Endoscopy | 3 | 2012 | 479 | 0.060 |
Why?
|
| Myocardial Reperfusion Injury | 2 | 1996 | 197 | 0.060 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2023 | 6915 | 0.060 |
Why?
|
| Oligopeptides | 1 | 2005 | 429 | 0.060 |
Why?
|
| Gene Frequency | 3 | 2019 | 1163 | 0.060 |
Why?
|
| Patient Readmission | 2 | 2018 | 548 | 0.060 |
Why?
|
| Isoenzymes | 1 | 2005 | 614 | 0.060 |
Why?
|
| Adenosine | 2 | 1996 | 289 | 0.060 |
Why?
|
| Precision Medicine | 2 | 2022 | 1154 | 0.050 |
Why?
|
| Logistic Models | 4 | 2016 | 3441 | 0.050 |
Why?
|
| Neuronavigation | 1 | 2003 | 47 | 0.050 |
Why?
|
| Coma | 1 | 2003 | 61 | 0.050 |
Why?
|
| Hepatitis A Virus Cellular Receptor 2 | 1 | 2022 | 59 | 0.050 |
Why?
|
| Thalidomide | 2 | 2018 | 569 | 0.050 |
Why?
|
| Growth Hormone | 1 | 2022 | 226 | 0.050 |
Why?
|
| Carcinoma, Papillary | 1 | 2006 | 584 | 0.050 |
Why?
|
| Neuroendocrine Tumors | 1 | 2008 | 634 | 0.050 |
Why?
|
| State Medicine | 1 | 2021 | 16 | 0.050 |
Why?
|
| Hepatectomy | 1 | 2008 | 1011 | 0.050 |
Why?
|
| Pyrroles | 1 | 2006 | 576 | 0.050 |
Why?
|
| Health Care Surveys | 1 | 2003 | 430 | 0.050 |
Why?
|
| Aspartate Aminotransferases | 1 | 2022 | 153 | 0.050 |
Why?
|
| Brain Stem | 1 | 2022 | 175 | 0.050 |
Why?
|
| Basal Ganglia Diseases | 1 | 2001 | 29 | 0.050 |
Why?
|
| Lasers | 1 | 2002 | 198 | 0.050 |
Why?
|
| Enema | 1 | 2001 | 47 | 0.050 |
Why?
|
| Alanine Transaminase | 1 | 2022 | 227 | 0.050 |
Why?
|
| Carcinoembryonic Antigen | 2 | 2015 | 222 | 0.050 |
Why?
|
| HLA-A1 Antigen | 1 | 2020 | 9 | 0.050 |
Why?
|
| Dimethyl Sulfoxide | 1 | 2021 | 52 | 0.050 |
Why?
|
| Technology | 1 | 2021 | 96 | 0.050 |
Why?
|
| Neurons | 1 | 2012 | 2287 | 0.050 |
Why?
|
| Microsurgery | 2 | 2014 | 244 | 0.050 |
Why?
|
| Solvents | 1 | 2021 | 66 | 0.050 |
Why?
|
| Immunotoxins | 1 | 2001 | 117 | 0.050 |
Why?
|
| Epidemiologic Methods | 1 | 2021 | 254 | 0.050 |
Why?
|
| Meningeal Neoplasms | 1 | 2005 | 441 | 0.050 |
Why?
|
| Phosphoproteins | 1 | 2006 | 1152 | 0.050 |
Why?
|
| Hypocalcemia | 1 | 2001 | 59 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2022 | 272 | 0.050 |
Why?
|
| Allopurinol | 1 | 2021 | 54 | 0.050 |
Why?
|
| Discriminant Analysis | 1 | 2020 | 48 | 0.050 |
Why?
|
| Magnesium | 1 | 2001 | 160 | 0.050 |
Why?
|
| Immunosuppressive Agents | 2 | 2010 | 1375 | 0.050 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2006 | 1265 | 0.050 |
Why?
|
| Rare Diseases | 1 | 2023 | 351 | 0.050 |
Why?
|
| Microsatellite Repeats | 1 | 2022 | 575 | 0.050 |
Why?
|
| Anorexia | 1 | 2001 | 143 | 0.050 |
Why?
|
| Hand Hygiene | 1 | 2020 | 14 | 0.050 |
Why?
|
| Intersectoral Collaboration | 1 | 2020 | 44 | 0.050 |
Why?
|
| Pyrimidinones | 1 | 2022 | 314 | 0.050 |
Why?
|
| Interleukin-2 | 1 | 2024 | 842 | 0.050 |
Why?
|
| Phosphates | 1 | 2001 | 187 | 0.050 |
Why?
|
| Organoids | 1 | 2022 | 287 | 0.050 |
Why?
|
| Fanconi Anemia Complementation Group N Protein | 1 | 2019 | 27 | 0.050 |
Why?
|
| Resource Allocation | 1 | 2020 | 67 | 0.050 |
Why?
|
| Exercise Therapy | 1 | 2023 | 288 | 0.050 |
Why?
|
| Catheterization, Central Venous | 1 | 2003 | 354 | 0.050 |
Why?
|
| Survival | 2 | 2013 | 177 | 0.050 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2020 | 173 | 0.040 |
Why?
|
| Pyridones | 1 | 2022 | 348 | 0.040 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2002 | 255 | 0.040 |
Why?
|
| Lymph Node Excision | 1 | 2007 | 1959 | 0.040 |
Why?
|
| Hematoma | 1 | 2001 | 160 | 0.040 |
Why?
|
| Databases, Factual | 3 | 2017 | 2218 | 0.040 |
Why?
|
| Celecoxib | 2 | 2013 | 200 | 0.040 |
Why?
|
| Injections, Intraperitoneal | 2 | 2010 | 197 | 0.040 |
Why?
|
| Microspheres | 1 | 2020 | 210 | 0.040 |
Why?
|
| Vomiting | 1 | 2001 | 354 | 0.040 |
Why?
|
| Fatigue | 2 | 2007 | 1239 | 0.040 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2020 | 247 | 0.040 |
Why?
|
| Comorbidity | 3 | 2016 | 2352 | 0.040 |
Why?
|
| Biomarkers | 2 | 2022 | 5047 | 0.040 |
Why?
|
| Bile Ducts | 1 | 2000 | 113 | 0.040 |
Why?
|
| ras Proteins | 2 | 2013 | 770 | 0.040 |
Why?
|
| Pelvic Neoplasms | 1 | 2001 | 189 | 0.040 |
Why?
|
| Venous Thrombosis | 1 | 2003 | 384 | 0.040 |
Why?
|
| Communication | 2 | 2019 | 876 | 0.040 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 1 | 2019 | 159 | 0.040 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2020 | 171 | 0.040 |
Why?
|
| Genetic Variation | 2 | 2006 | 2086 | 0.040 |
Why?
|
| Germ Cells | 1 | 2021 | 335 | 0.040 |
Why?
|
| Dose-Response Relationship, Radiation | 3 | 2006 | 726 | 0.040 |
Why?
|
| Cyclooxygenase 2 | 2 | 2013 | 483 | 0.040 |
Why?
|
| World Health Organization | 1 | 2020 | 316 | 0.040 |
Why?
|
| International Cooperation | 1 | 2020 | 323 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 2003 | 1363 | 0.040 |
Why?
|
| Vimentin | 1 | 2019 | 253 | 0.040 |
Why?
|
| DNA, Neoplasm | 2 | 2014 | 1910 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2015 | 1533 | 0.040 |
Why?
|
| Colostomy | 2 | 2013 | 70 | 0.040 |
Why?
|
| Catheter Ablation | 1 | 2004 | 620 | 0.040 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2020 | 675 | 0.040 |
Why?
|
| Pancreatic Cyst | 1 | 2019 | 107 | 0.040 |
Why?
|
| Phosphorylation | 3 | 2012 | 4804 | 0.040 |
Why?
|
| Genetic Markers | 2 | 1991 | 974 | 0.040 |
Why?
|
| HLA-B Antigens | 1 | 1998 | 57 | 0.040 |
Why?
|
| PPAR gamma | 1 | 2019 | 229 | 0.040 |
Why?
|
| Iron Overload | 1 | 1998 | 35 | 0.040 |
Why?
|
| Nervous System Diseases | 1 | 2003 | 500 | 0.040 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2019 | 182 | 0.040 |
Why?
|
| Hemochromatosis | 1 | 1998 | 35 | 0.040 |
Why?
|
| Infection Control | 1 | 2020 | 270 | 0.040 |
Why?
|
| Membrane Proteins | 2 | 2019 | 2819 | 0.040 |
Why?
|
| Hospitals, Low-Volume | 1 | 2018 | 53 | 0.040 |
Why?
|
| HLA-A Antigens | 1 | 1998 | 102 | 0.040 |
Why?
|
| Genotype | 4 | 2007 | 4109 | 0.040 |
Why?
|
| Child | 6 | 2020 | 29154 | 0.040 |
Why?
|
| Demography | 2 | 2014 | 435 | 0.040 |
Why?
|
| Cell Cycle Proteins | 2 | 2018 | 2045 | 0.040 |
Why?
|
| Cause of Death | 1 | 2021 | 752 | 0.040 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2018 | 109 | 0.040 |
Why?
|
| Reoperation | 2 | 2012 | 1382 | 0.040 |
Why?
|
| Perioperative Care | 1 | 2022 | 451 | 0.040 |
Why?
|
| Radiodermatitis | 1 | 2017 | 75 | 0.040 |
Why?
|
| Rabbits | 5 | 1997 | 957 | 0.040 |
Why?
|
| Sex Factors | 2 | 2017 | 2139 | 0.040 |
Why?
|
| Consolidation Chemotherapy | 1 | 2017 | 155 | 0.040 |
Why?
|
| Colonoscopy | 1 | 2001 | 518 | 0.040 |
Why?
|
| Carcinoma, Small Cell | 1 | 2000 | 408 | 0.040 |
Why?
|
| Anesthesia, Spinal | 1 | 1997 | 18 | 0.040 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2001 | 661 | 0.040 |
Why?
|
| Chromosome Mapping | 3 | 1991 | 1471 | 0.040 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 1998 | 235 | 0.040 |
Why?
|
| Azacitidine | 1 | 2023 | 1149 | 0.040 |
Why?
|
| Pancreatitis | 1 | 2019 | 267 | 0.040 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2017 | 160 | 0.040 |
Why?
|
| Length of Stay | 2 | 2018 | 1900 | 0.040 |
Why?
|
| Peritoneum | 1 | 2017 | 150 | 0.040 |
Why?
|
| Chromatography, Liquid | 1 | 2018 | 342 | 0.040 |
Why?
|
| Attitude of Health Personnel | 1 | 2003 | 918 | 0.040 |
Why?
|
| Ischemic Preconditioning, Myocardial | 1 | 1996 | 11 | 0.040 |
Why?
|
| Placenta | 1 | 2020 | 516 | 0.040 |
Why?
|
| Carboxylesterase | 1 | 2016 | 33 | 0.040 |
Why?
|
| Receptors, Adrenergic | 1 | 1996 | 46 | 0.040 |
Why?
|
| Pyruvate Dehydrogenase Complex | 1 | 1996 | 20 | 0.030 |
Why?
|
| Dichloroacetic Acid | 1 | 1996 | 15 | 0.030 |
Why?
|
| Margins of Excision | 1 | 2018 | 285 | 0.030 |
Why?
|
| Life Expectancy | 1 | 2016 | 129 | 0.030 |
Why?
|
| Enzyme Activation | 3 | 1996 | 1764 | 0.030 |
Why?
|
| Bortezomib | 1 | 2018 | 543 | 0.030 |
Why?
|
| Sympathetic Nervous System | 1 | 1997 | 159 | 0.030 |
Why?
|
| Genes, p53 | 1 | 2020 | 1090 | 0.030 |
Why?
|
| Egypt | 1 | 2015 | 42 | 0.030 |
Why?
|
| Breath Holding | 1 | 2015 | 44 | 0.030 |
Why?
|
| Pelvis | 1 | 2017 | 362 | 0.030 |
Why?
|
| Sphingosine | 1 | 1995 | 55 | 0.030 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2022 | 1048 | 0.030 |
Why?
|
| Human papillomavirus 18 | 1 | 2015 | 43 | 0.030 |
Why?
|
| Eligibility Determination | 1 | 2016 | 77 | 0.030 |
Why?
|
| Rectum | 1 | 2017 | 467 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2018 | 905 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2018 | 368 | 0.030 |
Why?
|
| Organ Sparing Treatments | 1 | 2017 | 277 | 0.030 |
Why?
|
| Japan | 2 | 2013 | 227 | 0.030 |
Why?
|
| Exercise | 1 | 2023 | 1183 | 0.030 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2020 | 1016 | 0.030 |
Why?
|
| HLA Antigens | 1 | 1998 | 546 | 0.030 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2013 | 340 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2016 | 486 | 0.030 |
Why?
|
| Glucose | 1 | 2021 | 1248 | 0.030 |
Why?
|
| Neurologic Examination | 1 | 2015 | 245 | 0.030 |
Why?
|
| Models, Biological | 2 | 2014 | 3254 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 2020 | 748 | 0.030 |
Why?
|
| Nerve Block | 1 | 1997 | 176 | 0.030 |
Why?
|
| Ethers, Cyclic | 1 | 1994 | 16 | 0.030 |
Why?
|
| Propensity Score | 1 | 2018 | 750 | 0.030 |
Why?
|
| Okadaic Acid | 1 | 1994 | 28 | 0.030 |
Why?
|
| Rupture | 1 | 2014 | 61 | 0.030 |
Why?
|
| Antigens, Surface | 1 | 1995 | 295 | 0.030 |
Why?
|
| Transcriptome | 1 | 2023 | 1859 | 0.030 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2014 | 88 | 0.030 |
Why?
|
| Physicians | 1 | 2003 | 882 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2016 | 665 | 0.030 |
Why?
|
| Equilibrative Nucleoside Transporter 1 | 1 | 2014 | 16 | 0.030 |
Why?
|
| Phenylisopropyladenosine | 1 | 1994 | 1 | 0.030 |
Why?
|
| Receptors, Purinergic P1 | 1 | 1994 | 25 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2013 | 2488 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2016 | 886 | 0.030 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2014 | 153 | 0.030 |
Why?
|
| Biological Transport, Active | 1 | 2014 | 131 | 0.030 |
Why?
|
| Cerebral Angiography | 1 | 2014 | 129 | 0.030 |
Why?
|
| Family Health | 1 | 2015 | 325 | 0.030 |
Why?
|
| Stroke | 1 | 2003 | 1144 | 0.030 |
Why?
|
| Myocardium | 3 | 1997 | 1313 | 0.030 |
Why?
|
| Lactic Acid | 1 | 1996 | 305 | 0.030 |
Why?
|
| Surgical Instruments | 1 | 2014 | 138 | 0.030 |
Why?
|
| Retinoblastoma Protein | 1 | 1995 | 335 | 0.030 |
Why?
|
| Telemedicine | 1 | 2020 | 471 | 0.030 |
Why?
|
| Protein Stability | 1 | 2015 | 370 | 0.030 |
Why?
|
| Diarrhea | 1 | 2017 | 686 | 0.030 |
Why?
|
| Cell Aggregation | 1 | 2013 | 61 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2014 | 573 | 0.030 |
Why?
|
| Body Temperature | 1 | 1994 | 158 | 0.030 |
Why?
|
| Myocardial Ischemia | 2 | 1994 | 435 | 0.030 |
Why?
|
| Genes, myc | 1 | 1995 | 358 | 0.030 |
Why?
|
| Human papillomavirus 16 | 1 | 2015 | 256 | 0.030 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2014 | 216 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2018 | 1869 | 0.030 |
Why?
|
| Diagnosis, Differential | 3 | 2008 | 4744 | 0.030 |
Why?
|
| ROC Curve | 2 | 2007 | 1183 | 0.030 |
Why?
|
| Child, Preschool | 4 | 2018 | 16273 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 2015 | 1037 | 0.030 |
Why?
|
| Anesthetics | 1 | 1994 | 115 | 0.030 |
Why?
|
| Phenotype | 3 | 2018 | 6295 | 0.030 |
Why?
|
| Substrate Specificity | 1 | 1994 | 549 | 0.030 |
Why?
|
| Genes, Neoplasm | 1 | 2014 | 324 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 2 | 2018 | 3101 | 0.030 |
Why?
|
| Biological Transport | 1 | 2014 | 597 | 0.030 |
Why?
|
| raf Kinases | 1 | 2013 | 81 | 0.030 |
Why?
|
| Indazoles | 1 | 2015 | 297 | 0.030 |
Why?
|
| Alcohol Drinking | 2 | 2007 | 551 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2014 | 875 | 0.030 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2015 | 304 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2016 | 1077 | 0.030 |
Why?
|
| DNA Damage | 1 | 2021 | 1954 | 0.030 |
Why?
|
| Serum Albumin | 1 | 2013 | 257 | 0.030 |
Why?
|
| Proteolysis | 1 | 2015 | 370 | 0.030 |
Why?
|
| Potassium Channels | 1 | 1994 | 162 | 0.030 |
Why?
|
| Age of Onset | 1 | 2015 | 827 | 0.030 |
Why?
|
| Dexamethasone | 1 | 2018 | 1450 | 0.030 |
Why?
|
| Nervous System | 1 | 2013 | 165 | 0.030 |
Why?
|
| Glasgow Coma Scale | 2 | 2003 | 215 | 0.030 |
Why?
|
| Cardiotonic Agents | 1 | 1994 | 151 | 0.030 |
Why?
|
| Contrast Media | 2 | 2012 | 1472 | 0.030 |
Why?
|
| Office Visits | 1 | 2013 | 97 | 0.030 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2018 | 854 | 0.030 |
Why?
|
| Islets of Langerhans | 1 | 2013 | 229 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2023 | 4078 | 0.030 |
Why?
|
| Biological Evolution | 2 | 1991 | 278 | 0.030 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2022 | 2370 | 0.030 |
Why?
|
| Alleles | 2 | 2006 | 2437 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2018 | 3203 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2018 | 1274 | 0.030 |
Why?
|
| Piperazines | 1 | 2021 | 2101 | 0.030 |
Why?
|
| NF-kappa B | 2 | 2010 | 1549 | 0.030 |
Why?
|
| Genetic Therapy | 1 | 2000 | 1616 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 2 | 2008 | 589 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2019 | 2483 | 0.030 |
Why?
|
| Asymptomatic Diseases | 1 | 2012 | 100 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2017 | 915 | 0.030 |
Why?
|
| Adenosine Triphosphate | 1 | 1994 | 571 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2015 | 953 | 0.030 |
Why?
|
| Niacinamide | 1 | 2013 | 421 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2019 | 4143 | 0.030 |
Why?
|
| Group Practice | 1 | 1971 | 18 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 1991 | 169 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2014 | 1546 | 0.020 |
Why?
|
| Dissection | 1 | 2011 | 156 | 0.020 |
Why?
|
| Cell Division | 1 | 1995 | 2489 | 0.020 |
Why?
|
| Pyrazoles | 2 | 2013 | 1471 | 0.020 |
Why?
|
| Leukopenia | 1 | 2011 | 151 | 0.020 |
Why?
|
| Genes | 2 | 1989 | 491 | 0.020 |
Why?
|
| Crossing Over, Genetic | 1 | 1991 | 56 | 0.020 |
Why?
|
| Tertiary Care Centers | 1 | 2013 | 403 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 1489 | 0.020 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2014 | 604 | 0.020 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2020 | 1763 | 0.020 |
Why?
|
| Dyspnea | 1 | 2013 | 416 | 0.020 |
Why?
|
| Proteomics | 1 | 2018 | 1380 | 0.020 |
Why?
|
| Radiography, Thoracic | 1 | 2013 | 462 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 2 | 1995 | 5395 | 0.020 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2011 | 170 | 0.020 |
Why?
|
| Exome | 1 | 2015 | 1239 | 0.020 |
Why?
|
| Blood Transfusion | 1 | 2013 | 583 | 0.020 |
Why?
|
| CDX2 Transcription Factor | 1 | 2009 | 37 | 0.020 |
Why?
|
| Fibrosis | 1 | 2013 | 793 | 0.020 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1991 | 362 | 0.020 |
Why?
|
| Phenylurea Compounds | 1 | 2013 | 580 | 0.020 |
Why?
|
| Genes, erbB-1 | 1 | 2009 | 101 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2012 | 1082 | 0.020 |
Why?
|
| Blood Loss, Surgical | 1 | 2011 | 309 | 0.020 |
Why?
|
| Cell Cycle | 1 | 1995 | 2084 | 0.020 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2014 | 755 | 0.020 |
Why?
|
| Aftercare | 1 | 2011 | 259 | 0.020 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2009 | 106 | 0.020 |
Why?
|
| Infusions, Parenteral | 1 | 2009 | 191 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2018 | 3821 | 0.020 |
Why?
|
| Genes, erbB-2 | 1 | 2009 | 229 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2010 | 392 | 0.020 |
Why?
|
| Keratins | 1 | 2009 | 330 | 0.020 |
Why?
|
| Tegafur | 1 | 2008 | 50 | 0.020 |
Why?
|
| Duodenum | 1 | 1969 | 149 | 0.020 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2009 | 129 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2016 | 1664 | 0.020 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2008 | 191 | 0.020 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2012 | 592 | 0.020 |
Why?
|
| Gastroenterology | 1 | 1971 | 195 | 0.020 |
Why?
|
| Karyotyping | 1 | 2010 | 1022 | 0.020 |
Why?
|
| Delayed-Action Preparations | 1 | 2008 | 208 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 1165 | 0.020 |
Why?
|
| Endovascular Procedures | 1 | 2014 | 516 | 0.020 |
Why?
|
| Recombination, Genetic | 2 | 2006 | 613 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2010 | 1062 | 0.020 |
Why?
|
| Heart | 1 | 1994 | 1223 | 0.020 |
Why?
|
| Sepsis | 1 | 2013 | 652 | 0.020 |
Why?
|
| Mice | 2 | 2023 | 34495 | 0.020 |
Why?
|
| Hospitalization | 2 | 2011 | 2083 | 0.020 |
Why?
|
| Pregnancy | 1 | 2020 | 7573 | 0.020 |
Why?
|
| X-ray Repair Cross Complementing Protein 1 | 1 | 2007 | 62 | 0.020 |
Why?
|
| International Agencies | 1 | 2007 | 107 | 0.020 |
Why?
|
| Appetite | 1 | 2007 | 73 | 0.020 |
Why?
|
| DNA Polymerase II | 1 | 2007 | 59 | 0.020 |
Why?
|
| Hematologic Diseases | 1 | 2008 | 242 | 0.020 |
Why?
|
| DNA-(Apurinic or Apyrimidinic Site) Lyase | 1 | 2007 | 66 | 0.020 |
Why?
|
| Gene Expression | 1 | 1995 | 3570 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 1995 | 2022 | 0.020 |
Why?
|
| Drug Approval | 1 | 2008 | 178 | 0.020 |
Why?
|
| Face | 1 | 1989 | 273 | 0.020 |
Why?
|
| Southwestern United States | 1 | 2006 | 62 | 0.020 |
Why?
|
| SEER Program | 1 | 2010 | 1000 | 0.020 |
Why?
|
| Matched-Pair Analysis | 1 | 2006 | 103 | 0.020 |
Why?
|
| Health Promotion | 1 | 2011 | 502 | 0.020 |
Why?
|
| Base Sequence | 2 | 1991 | 4917 | 0.020 |
Why?
|
| United States Food and Drug Administration | 1 | 2008 | 332 | 0.020 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 2006 | 69 | 0.020 |
Why?
|
| Medical Records | 1 | 2008 | 415 | 0.020 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2006 | 132 | 0.020 |
Why?
|
| Carcinoid Tumor | 1 | 2008 | 280 | 0.020 |
Why?
|
| Genome, Human | 1 | 2014 | 1869 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 1989 | 641 | 0.020 |
Why?
|
| Triiodobenzoic Acids | 1 | 2006 | 68 | 0.020 |
Why?
|
| Infant | 3 | 2010 | 13310 | 0.020 |
Why?
|
| Anemia | 1 | 2011 | 689 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2011 | 2927 | 0.020 |
Why?
|
| Ventricular Fibrillation | 2 | 1997 | 61 | 0.020 |
Why?
|
| RecQ Helicases | 1 | 2006 | 102 | 0.020 |
Why?
|
| Diabetes Complications | 1 | 2007 | 305 | 0.020 |
Why?
|
| Environment | 1 | 2006 | 190 | 0.020 |
Why?
|
| Elective Surgical Procedures | 1 | 2007 | 250 | 0.020 |
Why?
|
| Pulse Therapy, Drug | 1 | 2004 | 12 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2006 | 409 | 0.020 |
Why?
|
| Depsipeptides | 1 | 2005 | 78 | 0.020 |
Why?
|
| Metals | 1 | 2005 | 155 | 0.020 |
Why?
|
| Ultrasonography, Interventional | 1 | 2008 | 429 | 0.020 |
Why?
|
| Genetics, Medical | 1 | 1986 | 143 | 0.020 |
Why?
|
| Sampling Studies | 1 | 2004 | 170 | 0.020 |
Why?
|
| Streptozocin | 1 | 2004 | 75 | 0.020 |
Why?
|
| Glasgow Outcome Scale | 1 | 2004 | 47 | 0.020 |
Why?
|
| Chromosome Deletion | 1 | 1989 | 1005 | 0.020 |
Why?
|
| Data Collection | 1 | 2007 | 620 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2012 | 4307 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2009 | 1143 | 0.020 |
Why?
|
| Myocardial Reperfusion | 2 | 1994 | 108 | 0.020 |
Why?
|
| Fertilization | 1 | 1984 | 56 | 0.010 |
Why?
|
| Italy | 1 | 2004 | 236 | 0.010 |
Why?
|
| Sleep Wake Disorders | 1 | 2007 | 348 | 0.010 |
Why?
|
| Adenosine Triphosphatases | 1 | 2006 | 435 | 0.010 |
Why?
|
| DNA Helicases | 1 | 2006 | 434 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1991 | 6089 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2009 | 2508 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2005 | 553 | 0.010 |
Why?
|
| Hepatitis C | 1 | 2008 | 524 | 0.010 |
Why?
|
| Societies, Medical | 1 | 1969 | 1335 | 0.010 |
Why?
|
| Folic Acid | 1 | 2005 | 349 | 0.010 |
Why?
|
| Probability | 1 | 2004 | 866 | 0.010 |
Why?
|
| Heart Rate | 2 | 1997 | 737 | 0.010 |
Why?
|
| Radiology | 1 | 2007 | 434 | 0.010 |
Why?
|
| Risk | 1 | 2006 | 1972 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2003 | 495 | 0.010 |
Why?
|
| Activities of Daily Living | 1 | 2004 | 552 | 0.010 |
Why?
|
| Spermatozoa | 1 | 1984 | 315 | 0.010 |
Why?
|
| Oocytes | 1 | 1984 | 414 | 0.010 |
Why?
|
| Health Surveys | 1 | 2003 | 402 | 0.010 |
Why?
|
| Trastuzumab | 1 | 2004 | 696 | 0.010 |
Why?
|
| Age Distribution | 1 | 2003 | 698 | 0.010 |
Why?
|
| Cell Line | 3 | 1995 | 5114 | 0.010 |
Why?
|
| Apoptosis | 1 | 1995 | 7591 | 0.010 |
Why?
|
| Primary Prevention | 1 | 2003 | 255 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2013 | 7226 | 0.010 |
Why?
|
| Thrombolytic Therapy | 1 | 2003 | 257 | 0.010 |
Why?
|
| Blood Glucose | 2 | 1996 | 1244 | 0.010 |
Why?
|
| Coronary Vessels | 2 | 1994 | 665 | 0.010 |
Why?
|
| Blood Pressure | 2 | 1997 | 1467 | 0.010 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2001 | 566 | 0.010 |
Why?
|
| Vascular Surgical Procedures | 1 | 2004 | 655 | 0.010 |
Why?
|
| Pain | 1 | 2007 | 1658 | 0.010 |
Why?
|
| Hemochromatosis Protein | 1 | 1998 | 23 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2004 | 2315 | 0.010 |
Why?
|
| Transferrin | 1 | 1998 | 78 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 1984 | 1620 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2004 | 2232 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2001 | 1382 | 0.010 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2004 | 705 | 0.010 |
Why?
|
| Ferritins | 1 | 1998 | 151 | 0.010 |
Why?
|
| Electrons | 1 | 1998 | 168 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2004 | 3005 | 0.010 |
Why?
|
| Tyramine | 1 | 1996 | 4 | 0.010 |
Why?
|
| Phentolamine | 1 | 1996 | 26 | 0.010 |
Why?
|
| Theophylline | 1 | 1996 | 34 | 0.010 |
Why?
|
| Prazosin | 1 | 1996 | 22 | 0.010 |
Why?
|
| Receptors, Adrenergic, alpha | 1 | 1996 | 15 | 0.010 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 1996 | 42 | 0.010 |
Why?
|
| Mink | 1 | 1995 | 8 | 0.010 |
Why?
|
| Retinoblastoma-Binding Protein 1 | 1 | 1995 | 54 | 0.010 |
Why?
|
| Transcription Factor DP1 | 1 | 1995 | 57 | 0.010 |
Why?
|
| Sphingomyelins | 1 | 1995 | 33 | 0.010 |
Why?
|
| Haplotypes | 1 | 1998 | 856 | 0.010 |
Why?
|
| E2F Transcription Factors | 1 | 1995 | 132 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2002 | 2803 | 0.010 |
Why?
|
| Hydrolysis | 1 | 1995 | 227 | 0.010 |
Why?
|
| Amines | 1 | 1995 | 85 | 0.010 |
Why?
|
| Norepinephrine | 1 | 1996 | 272 | 0.010 |
Why?
|
| Organ Size | 1 | 1997 | 690 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 1995 | 394 | 0.010 |
Why?
|
| Constriction | 1 | 1994 | 55 | 0.010 |
Why?
|
| Leukemia, Lymphoid | 1 | 1995 | 276 | 0.010 |
Why?
|
| Pentobarbital | 1 | 1994 | 29 | 0.010 |
Why?
|
| Iron | 1 | 1998 | 376 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2006 | 3343 | 0.010 |
Why?
|
| Isoflurane | 1 | 1994 | 67 | 0.010 |
Why?
|
| fas Receptor | 1 | 1995 | 185 | 0.010 |
Why?
|
| Lidocaine | 1 | 1994 | 76 | 0.010 |
Why?
|
| Retinoblastoma | 1 | 1995 | 200 | 0.010 |
Why?
|
| Potassium Channel Blockers | 1 | 1994 | 110 | 0.010 |
Why?
|
| Protein Kinase C | 1 | 1995 | 396 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 1995 | 931 | 0.010 |
Why?
|
| Eye Neoplasms | 1 | 1995 | 247 | 0.010 |
Why?
|
| Kinetics | 1 | 1995 | 2049 | 0.010 |
Why?
|
| Reference Values | 1 | 1994 | 1099 | 0.010 |
Why?
|
| Hemodynamics | 1 | 1996 | 935 | 0.010 |
Why?
|
| Ketamine | 1 | 1994 | 234 | 0.010 |
Why?
|
| Swine | 1 | 1994 | 1541 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 1989 | 264 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 1989 | 406 | 0.010 |
Why?
|
| Cell Survival | 1 | 1995 | 3045 | 0.010 |
Why?
|
| Vagotomy | 1 | 1948 | 26 | 0.010 |
Why?
|
| Methylation | 1 | 1989 | 597 | 0.000 |
Why?
|
| Gastroscopy | 1 | 1948 | 134 | 0.000 |
Why?
|
| Sarcoma, Ewing | 1 | 1991 | 406 | 0.000 |
Why?
|
| Cosmids | 1 | 1987 | 40 | 0.000 |
Why?
|
| DNA Restriction Enzymes | 1 | 1987 | 117 | 0.000 |
Why?
|
| Transcription, Genetic | 1 | 1995 | 3154 | 0.000 |
Why?
|
| Mucous Membrane | 1 | 1948 | 271 | 0.000 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1987 | 542 | 0.000 |
Why?
|
| Translocation, Genetic | 1 | 1991 | 1245 | 0.000 |
Why?
|
| Syndrome | 1 | 1989 | 1351 | 0.000 |
Why?
|
| RNA, Messenger | 1 | 1995 | 6150 | 0.000 |
Why?
|
| Stomach | 1 | 1948 | 387 | 0.000 |
Why?
|
| Chromosomes, Human | 1 | 1986 | 295 | 0.000 |
Why?
|
| Iodoacetamide | 1 | 1984 | 2 | 0.000 |
Why?
|
| Diamide | 1 | 1984 | 5 | 0.000 |
Why?
|
| Gastric Mucosa | 1 | 1948 | 613 | 0.000 |
Why?
|
| Disulfides | 1 | 1984 | 116 | 0.000 |
Why?
|
| Cystic Fibrosis | 1 | 1986 | 264 | 0.000 |
Why?
|
| Cricetinae | 1 | 1984 | 706 | 0.000 |
Why?
|
| Oxidation-Reduction | 1 | 1984 | 717 | 0.000 |
Why?
|
| Lymphocytes | 1 | 1987 | 1234 | 0.000 |
Why?
|
| Pedigree | 1 | 1986 | 1890 | 0.000 |
Why?
|
| Insulin | 1 | 1987 | 1454 | 0.000 |
Why?
|